Light Mode
$1.71 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.71, $0.05 below the day’s high of $1.76
-3.16 (-64.89%) / 6M
Momentum, market sentiment, and recent alerts
BCAB reads neutral: price sits above one of the two key moving averages, the 12-month move is +125.0%.
No alerts for BCAB in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
No peer group available for this symbol.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.